In this regard, in APP/PS1 transgenic mice, a model of Alzheimer’s disease, chronic treatment with ciproxifan reduced both COX-1 and COX-2 activities, decreased the level of pro-inflammatory cytokines IL-1α, IL-1β, and IL-6, and increased the level of anti-inflammatory cytokine TGF-1β [83]. The gene discussed is IL6; the disease is early-onset autosomal dominant Alzheimer disease.